223 related articles for article (PubMed ID: 34901581)
1. Developing Structure-Activity Relationships for
Cross KP; Ponting DJ
Comput Toxicol; 2021 Nov; 20():. PubMed ID: 34901581
[TBL] [Abstract][Full Text] [Related]
2. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
[TBL] [Abstract][Full Text] [Related]
3. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
[TBL] [Abstract][Full Text] [Related]
4. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency.
Snodin DJ; Trejo-Martin A; Ponting DJ; Smith GF; Czich A; Cross K; Custer L; Elloway J; Greene N; Kalgutkar AS; Stalford SA; Tennant RE; Vock E; Zalewski A; Ziegler V; Dobo KL
Chem Res Toxicol; 2024 Feb; 37(2):181-198. PubMed ID: 38316048
[TBL] [Abstract][Full Text] [Related]
6. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
7. Setting limits for N-nitrosamines in drugs: A defined approach based on read-across and structure-activity relationship for N-nitrosopiperazine impurities.
Dos Santos CEM; Dorta DJ; de Oliveira DP
Regul Toxicol Pharmacol; 2022 Dec; 136():105288. PubMed ID: 36384172
[TBL] [Abstract][Full Text] [Related]
8. Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damage.
Fine J; Allain L; Schlingemann J; Ponting DJ; Thomas R; Johnson GE
Regul Toxicol Pharmacol; 2023 Dec; 145():105505. PubMed ID: 37805106
[TBL] [Abstract][Full Text] [Related]
9. Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies.
Felter SP; Ponting DJ; Mudd AM; Thomas R; Oliveira AAF
Regul Toxicol Pharmacol; 2023 Sep; 143():105459. PubMed ID: 37474097
[TBL] [Abstract][Full Text] [Related]
10. Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines.
Thomas R; Thresher A; Ponting DJ
Regul Toxicol Pharmacol; 2021 Apr; 121():104875. PubMed ID: 33556416
[TBL] [Abstract][Full Text] [Related]
11. Quantum Mechanical Assessment of Nitrosamine Potency.
De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA
Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898
[TBL] [Abstract][Full Text] [Related]
12. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
Snodin DJ
Regul Toxicol Pharmacol; 2023 Jun; 141():105403. PubMed ID: 37116739
[TBL] [Abstract][Full Text] [Related]
13. Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of
Chakravarti S
Chem Res Toxicol; 2023 Jun; 36(6):959-970. PubMed ID: 37267457
[TBL] [Abstract][Full Text] [Related]
14. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
[TBL] [Abstract][Full Text] [Related]
15. Strategies for Assessing Acceptable Intakes for Novel
Ponting DJ; Dobo KL; Kenyon MO; Kalgutkar AS
J Med Chem; 2022 Dec; 65(23):15584-15607. PubMed ID: 36441966
[TBL] [Abstract][Full Text] [Related]
16. Permitted daily exposure limits for noteworthy N-nitrosamines.
Johnson GE; Dobo K; Gollapudi B; Harvey J; Kenny J; Kenyon M; Lynch A; Minocherhomji S; Nicolette J; Thybaud V; Wheeldon R; Zeller A
Environ Mol Mutagen; 2021 Jun; 62(5):293-305. PubMed ID: 34089278
[TBL] [Abstract][Full Text] [Related]
17. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
18. Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA).
Bercu JP; Masuda-Herrera M; Johnson G; Czich A; Glowienke S; Kenyon M; Thomas R; Ponting DJ; White A; Cross K; Waechter F; Rodrigues MAC
Regul Toxicol Pharmacol; 2021 Jul; 123():104926. PubMed ID: 33862169
[TBL] [Abstract][Full Text] [Related]
19. Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs).
Bercu JP; Masuda-Herrera M; Trejo-Martin A; Sura P; Jolly R; Kenyon M; Thomas R; Ponting DJ; Snodin D; Tuschl G; Simon S; De Vlieger K; Hutchinson R; Czich A; Glowienke S; Reddy MV; Johanssen S; Vock E; Claude N; Weaver RJ
Regul Toxicol Pharmacol; 2023 Aug; 142():105415. PubMed ID: 37257751
[TBL] [Abstract][Full Text] [Related]
20. Application of an optimized total N-nitrosamine (TONO) assay to pools: placing N-nitrosodimethylamine (NDMA) determinations into perspective.
Kulshrestha P; McKinstry KC; Fernandez BO; Feelisch M; Mitch WA
Environ Sci Technol; 2010 May; 44(9):3369-75. PubMed ID: 20355696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
